Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $779,920.74 in Stock

Key Points

• Supernus Pharmaceuticals CEO Jack Khattar sold 16,587 shares of stock worth $779,920.74, reducing his ownership by 1.46% to approximately 1.12 million shares.
• The stock price of Supernus Pharmaceuticals recently decreased by 0.3%, trading at $46.83, despite a positive market outlook with several analysts raising their target prices.
• Analysts have varying ratings on Supernus Pharmaceuticals, with a consensus rating of "Buy" and a target price of $43.00, reflecting optimism about the company's performance.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 16,587 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $47.02, for a total value of $779,920.74. Following the sale, the chief executive officer directly owned 1,122,456 shares in the company, valued at $52,777,881.12. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Supernus Pharmaceuticals Stock Down 0.3%

NASDAQ SUPN traded down $0.15 during trading hours on Tuesday, hitting $46.83. 736,536 shares of the company were exchanged, compared to its average volume of 646,328. The stock has a 50-day moving average price of $40.93 and a 200 day moving average price of $35.18. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $47.65. The stock has a market cap of $2.63 billion, a PE ratio of 40.72 and a beta of 0.79.

Analysts Set New Price Targets

SUPN has been the subject of several recent analyst reports. Piper Sandler boosted their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research report on Friday, August 29th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $43.00.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently bought and sold shares of SUPN. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals in the first quarter worth approximately $30,000. Versant Capital Management Inc raised its stake in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals in the first quarter worth approximately $41,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $42,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Supernus Pharmaceuticals in the first quarter worth approximately $46,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.